skip to Main Content
MENU

ZebraTOXIfish® Safety pharmacology identify potential adverse effects in drug candidates early in the drug development pipeline, contributing to reduces the overall cost of the drug-discovery phase. Faster, cheaper and more reliable assays based on zebrafish are being developed as major tools for assessing toxicity of chemicals during the drug-discovery process.

Acute Toxicity Assay

The analysis of the subject allows to determine short- and medium-term (7 days) toxicity using zebrafish embryos in the early stages of their development. The test uses the LD50 (lethal dose 50) to determine the potential safety or toxicity of the compounds.

LD50

Chronic toxicity Assay

This assay allows us to calculate the no-observed-effect-concentration (NOEC) and the lowest-observed-effect-concentration (LOEC). Furthermore, Ikan conducts long-term studies on the effect of target compound in reproducing adults and in the new progeny development, analysing the teratogenicity among other variables.

Reproduction and growth effects, sublethal effects NOEC, LOEC.

ADME assay

Due to complications of in vivo adsorption, distribution, metabolism and excretion (ADME), the toxicity is a major cause of failure during drug development. Many drugs shown to be safe in cell culture prove toxic in animal studies. Effective in vivo toxicity screening early in the development process reduces the number of compounds that progress to laborious and costly late-stage animal testing. Ikan provides the methodology to obtain more information about the bioavailability of novel compounds.

Testing compound presence in tissues and water.

Hepatotoxicity assay

This service is complementary to the Acute Toxicity test. It permits the assessment of potential drug-induced liver injuries (DILI) that is one of the main reasons for rejection by the FDA.

Size modification, Necrosis, Steatosis.

Genotoxicity toxicity assay

Genotoxicity describes the property of chemical agents that damage the genetic material within a cell causing mutations, which may lead to cancer. The alteration can have direct or indirect effects on the DNA: the induction of mutations, mistimed event activation, and direct DNA damage leading to mutations. Ikan performs micronucleus and comet assays, thus providing a method for evaluating potential drugs.

Comet assay, micronucleus.

Cardiotoxicty

One not of the most relevant trials that are carried out for the evaluation of the safety of drugs consisting in observing the effect they cause on cardiac function. Ikan carries out cardiotoxicity assays to evaluate the potential cardiotoxicty of drugs by observing zebrafish’s ECG patterns which are similar to the ECG of humans.

ECG patterns.